PASG – passage bio, inc. (US:NASDAQ)
Stock Stats
News
11/21
10:52 am
pasg
Low
The GenScript Biotech Global Forum Makes a Strong Debut in Europe, Highlighting Breakthroughs in Cell and Gene Therapy Development [Yahoo! Finance]
11/14
06:30 pm
pasg
High
Passage Bio, Inc. (NASDAQ: PASG) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $7.00 price target on the stock.
11/14
11:13 am
pasg
Low
Passage Bio, Inc. (NASDAQ: PASG) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $13.00 price target on the stock.
11/14
07:39 am
pasg
Medium
Passage Bio Achieves Milestones in Gene Therapy Trials [Yahoo! Finance]
11/13
07:00 am
pasg
High
Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
11/13/2024
07:00 am
pasg
-13.1%
MISS
8/8/2024
07:00 am
pasg
-5.4%
BEAT
5/14/2024
07:00 am
pasg
-8.6%
BEAT
3/4/2024
07:00 am
pasg
3.6%
BEAT
11/14
06:30 pm
Reiterates
Buy
Buy
Chardan Capital
High
-13.5%
11/14
05:50 pm
Maintains
Buy
Buy
Chardan Capital
High
-13.5%
11/14
11:11 am
Maintains
Buy
Buy
Canaccord Genuity
Low
-1.1%
9/3
09:01 am
Initiates
Buy
Rodman & Renshaw
High
-12.9%
9/3
09:01 am
Initiates
Buy
Rodman & Renshaw
High
-12.9%
11/14
05:22 pm
pasg
High
Form SCHEDULE 13G/A Passage BIO, Inc. Filed by: Erste Asset Management GmbH
11/14
05:03 pm
pasg
High
Form SCHEDULE 13G Passage BIO, Inc. Filed by: Erste Asset Management GmbH
11/14
12:03 pm
pasg
Low
Form SC 13G Passage BIO, Inc. Filed by: Vestal Point Capital, LP
11/13
07:16 am
pasg
High
Form 10-Q Passage BIO, Inc. For: Sep 30
11/13
07:01 am
pasg
High
Form 8-K Passage BIO, Inc. For: Nov 13
Show more
Top News Gainers
3/27 Form 8-K Passage BIO, Inc. For: Mar 26 25.5%
3/24 Passage Bio (NASDAQ: PASG) is now covered by analysts at Goldman Sachs Group Inc. They set a "buy" rating on the stock. 12.2%
4/10 Passage Bio (NASDAQ: PASG) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $18.00 price target on the stock. 10.1%
5/1 Passage Bio (NASDAQ: PASG) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $21.00 price target on the stock. 8.1%
3/25 Passage Bio (NASDAQ: PASG) is now covered by analysts at Chardan Capital. They set a "buy" rating on the stock. 5.1%
3/9 Passage Bio Announces Exercise of Underwriters’ Option to Purchase Additional Shares 4.6%
2/28 Passage Bio shares soar 19% in their trading debut despite massive market selloff [MarketWatch] 3.3%
3/3 Form 4 Passage BIO, Inc. For: Mar 03 Filed by: Cale Edgar B. 3.0%
3/5 Bankers try to keep IPO party going amid coronavirus market jitters [Reuters] 2.3%
4/14 Form 8-K Passage BIO, Inc. For: Apr 10 2.1%
Top News Decliners
3/15 Coronavirus and market volatility shuts down the IPO market for potential listings like Airbnb [CNBC] -33.8%
3/25 Form 4 Passage BIO, Inc. For: Mar 24 Filed by: Countouriotis Athena -19.8%
3/6 Form SC 13G Passage BIO, Inc. Filed by: Vivo Capital VIII, LLC -9.4%
3/26 Form SEC STAFF LETTER Passage BIO, Inc. -8.1%
4/21 FDA Grants Passage Bio Orphan Drug Designation for PBGM01 for Treatment of Infantile GM1 Gangliosidosis -7.4%
3/12 Form 3/A Passage BIO, Inc. For: Feb 27 Filed by: Ratcliffe Liam -7.1%
3/2 Form 4 Passage BIO, Inc. For: Feb 27 Filed by: SQUINTO STEPHEN P -7.0%
3/12 Form SC 13G Passage BIO, Inc. Filed by: Access Industries Holdings LLC -6.7%
4/23 Passage Bio (NASDAQ: PASG) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.1%
4/3 Form 8-K Passage BIO, Inc. For: Apr 03 -3.9%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3